-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4%
Repare Therapeutics (NASDAQ:RPTX) Stock Price Down 4%
Repare Therapeutics Inc. (NASDAQ:RPTX – Get Rating) fell 4% during mid-day trading on Friday . The stock traded as low as $14.48 and last traded at $14.50. 4,560 shares changed hands during trading, a decline of 98% from the average session volume of 182,819 shares. The stock had previously closed at $15.11.
Analyst Ratings Changes
Separately, HC Wainwright lowered their price objective on shares of Repare Therapeutics from $38.00 to $25.00 and set a "buy" rating for the company in a research note on Thursday, November 17th. One investment analyst has rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat.com, Repare Therapeutics currently has an average rating of "Moderate Buy" and an average target price of $31.50.
Get Repare Therapeutics alerts:Repare Therapeutics Trading Down 2.6 %
The business's 50-day moving average is $15.53 and its two-hundred day moving average is $13.91. The stock has a market capitalization of $617.23 million, a PE ratio of -20.15 and a beta of 0.06.
Insider Buying and Selling
In related news, Director Davis Jerel sold 250,000 shares of the company's stock in a transaction on Friday, December 9th. The shares were sold at an average price of $16.00, for a total transaction of $4,000,000.00. Following the completion of the sale, the director now directly owns 2,094,451 shares of the company's stock, valued at approximately $33,511,216. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. 33.60% of the stock is owned by corporate insiders.Institutional Trading of Repare Therapeutics
Institutional investors have recently added to or reduced their stakes in the business. Bartlett & Co. LLC purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $28,000. UBS Group AG boosted its position in Repare Therapeutics by 26.3% in the 3rd quarter. UBS Group AG now owns 3,551 shares of the company's stock valued at $43,000 after buying an additional 739 shares during the last quarter. Bpifrance SA purchased a new position in Repare Therapeutics in the 2nd quarter valued at about $113,000. Tower Research Capital LLC TRC purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $113,000. Finally, Fox Run Management L.L.C. purchased a new position in Repare Therapeutics in the 3rd quarter valued at about $143,000. 78.19% of the stock is owned by hedge funds and other institutional investors.
About Repare Therapeutics
(Get Rating)
Repare Therapeutics Inc, a clinical-stage precision oncology company, discovers and develops therapeutics by using its synthetic lethality approach in Canada and the United States. The company uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform to systematically discover and develop highly targeted cancer therapies that focuses on genomic instability, including DNA damage repair.
See Also
- Get a free copy of the StockNews.com research report on Repare Therapeutics (RPTX)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Is Kintara Therapeutics A Hidden Gem?
- Should You Warm up to Generac Stock for the Winter?
Receive News & Ratings for Repare Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repare Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
Repare Treateutics Inc.(纳斯达克代码:RPTX-GET评级)周五午盘下跌4%。该股最低交易价格为14.48美元,最新报14.50美元。4,560股股票在交易中易手,较182,819股的平均成交量下降了98%。该股此前收盘价为15.11美元。
分析师评级发生变化
另外,HC Wainwright在11月17日星期四的一份研究报告中将Repare Treeutics的股票目标价从38.00美元下调至25.00美元,并为该公司设定了“买入”评级。一名投资分析师对该股的评级为持有,四名分析师对该公司的评级为买入。根据MarketBeat.com的数据,Repare Treeutics目前的平均评级为“中等买入”,平均目标价为31.50美元。
到达修复治疗学警报:Repare治疗公司股价下跌2.6%
该业务的50日移动均线切入位在15.53美元,200日移动均线切入位在13.91美元。该股市值为6.1723亿美元,市盈率为-20.15,贝塔系数为0.06。
内幕买卖
在相关新闻中,董事戴维斯·杰里尔在12月9日(星期五)的一笔交易中出售了250,000股该公司股票。这些股票的平均价格为16.00美元,总成交金额为4,000,000.00美元。出售完成后,董事现在直接拥有该公司2,094,451股股票,价值约33,511,216美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过美国证券交易委员会网站。33.60%的股份由公司内部人士持有。Repare治疗药物的制度性交易
机构投资者最近增持或减持了该公司的股份。Bartlett&Co.LLC在第二季度购买了Repare治疗公司的一个新头寸,价值约2.8万美元。瑞银集团(UBS Group AG)在第三季度将其在Repare Treeutics的头寸增加了26.3%。瑞银集团(UBS Group AG)目前持有该公司3,551股股票,价值43,000美元,上一季度又购买了739股。Bpifrance SA在第二季度购买了Repare治疗公司的一个新头寸,价值约11.3万美元。Tower Research Capital LLC TRC在第三季度购买了Repare治疗公司的一个新头寸,价值约11.3万美元。最后,Fox Run Management L.L.C.在第三季度购买了Repare治疗公司的一个新头寸,价值约143,000美元。78.19%的股票由对冲基金和其他机构投资者持有。
关于Repare Treeutics
(获取评级)
Repare治疗公司是一家临床阶段的精确肿瘤学公司,通过在加拿大和美国使用其合成致命性方法来发现和开发治疗方法。该公司使用其SNIPRx,这是一个专有的、全基因组的和支持CRISPR的平台,以系统地发现和开发专注于基因组不稳定性(包括DNA损伤修复)的高度针对性的癌症疗法。
另请参阅
- 免费获取StockNews.com关于Repare治疗的研究报告(RPTX)
- MarketBeat:回顾一周12/26-12/30
- 科技狗:是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗?
- 金塔拉治疗公司是一颗隐藏的宝石吗?
- 你应该热身到Generac股票过冬吗?
接受Repare治疗日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Repare Treeutics和相关公司的最新新闻和分析师评级的每日简要摘要。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧